

Telefax



No. of pages incl. this: 15

Telefax no.: (703) 308-4242

FAX RECEIVED  
MAR 07 2001  
GROUP 1600

Date: March 6, 2001

To: Examiner Slobodyansky

cc:

From: Elias Cambiris

OFFICIAL

Message:

Confidential information may be contained in this fax and is intended only for the use of the addressee. If you are not the addressee, please do not copy or deliver this to anyone else. If you receive this telefax by mistake, please telephone the sender. **Thank you.**

**Novozymes**  
**North America, Inc.**  
Patents

405 Lexington Av.,  
Suite 6400  
New York  
NY 10174

Telephone:  
(212)-867-0123  
Telefax:  
(212)-867-0298

Web:  
[www.novozymes.com](http://www.novozymes.com)

Attorney Docket No.: 4887.204-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Serial No.: 09/261,329

Group Art Unit: 1652

Filed: March 3, 1999

Examiner: E. Slobodyansky

Confirmation No: 7632

For: Cellulase Variants

FAX RECEIVED

MAR 07 2001

GROUP 1600

## CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents  
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner E. Slobodyanskyfax number (703) 308-4242.

Respectfully submitted,

Date: March 6, 2001



Elias J. Lambiris  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

OFFICIAL

Attorney Docket No.: 4887.204-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Serial No.: 09/261,329

Group Art Unit: 1652

Filed: March 3, 1999

Examiner: E. Slobodyansky

Confirmation No: 7632

For: Cellulase Variants

## AMENDMENT FEE TRANSMITTAL

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed September 6, 2000.

It is respectfully requested that the time for response to the Office Action be extended for a period of three months from December 6, 2000 to March 6, 2001. The required fee for the extension is estimated to be \$890.

The fee for claims has been calculated as shown below:

Total:  $42 - 36 = 6 \times 18 = \$108$


Independent:  $1 - 17 = x \times 80 = \$0$

Total additional fee for claims required is \$108.

Please charge the required extension and claims fees, estimated to be \$998.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: March 6, 2001

  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Attorney Docket No.: 4887.204-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Andersen et al.

Application No.: 09/261,329

Group Art Unit: 1652

Filed: March 3, 1999

Examiner: E. Slobodyansky

Confirmation No: 7632

For: Cellulase Variants

**AMENDMENT UNDER 37 C.F.R. 1.111**Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Office Action mailed September 6, 2000, please amend the above-captioned application as follows:

**IN THE CLAIMS:**

✓ Please cancel claims 1-36 without prejudice or disclaimer. Please add new claims 37-78.

37. A modified cellulase having endoglucanase activity, comprising a mutation in an amino acid sequence of a cellulase at one or more positions selected from the group consisting of: 22, 24, 25, 26, 29, 32, 33, 34, 35, 40, 42, 42a, 43, 49, 49a, 49b, 50, 53, 54, 64, 68, 69, 70, 71, 76, 79, 80, 84, 85, 86, 87, 88, 89, 91, 92, 93, 95d, 95h, 95j, 106, 127, 137, 138, 139, 140, 140a, 141, 149, 150b, 150e, 150j, 151, 152, 153, 154, 155, 156, 157, 159, 160c, 160e, 160k, 161, 164, 165, 166, 168, 169, 170, 171, 172, 173, 174, 188, 191, 192, 193, 195, 197, 200 and 201, wherein each mutation is independently a substitution, insertion or deletion and each position is numbered according to the amino acid sequence of the cellulase of SEQ ID NO:1.

38. A modified cellulase of claim 37, wherein the mutation comprises a substitution, insertion or deletion at position 22.

03/09/2001 GTRAMMEL 00000005 501701 09261329

01 FC:117 890.00 CH  
02 FC:103 108.00 CH11/8  
09/3  
3/9/0181  
muta-  
tion